• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Turn Biotechnologies launches delivery system for nucleic acid therapeutics

September 13, 2022 By Sean Whooley

Turn Biotechnologies
[Image from Turn Biotechnologies]
Turn Biotechnologies announced today that it created a novel platform for the safe and effective delivery of nucleic acid therapeutics.

Mountain View, California-based Turn said in a news release that the platform represents a “major expansion” of its business.

It designed its eTurna Platform for the next generation of precision medicine. eTurna allows for fine-tuning a variety of cargoes requiring different administration routes targeted to specific tissues nad cells. The company said it will use eTurna to deliver mRNA medicines developed using its epigenetic reprogramming of aging (ERA) platform.

eTurna can also carry other therapeutic cargoes. The company said collaborations to do so would unlock the potential of emerging therapeutics while feeling its expansion.

“Our platform overcomes the ultimate barrier to mRNA medicine by making it possible to deliver therapies precisely to their targets,” said Anja Krammer, Turn Bio CEO. “It is also extremely versatile, capable of encapsulating and stabilizing mRNAs and large cargo to produce formulations that can be developed for a wide array of therapies to transform how we treat disease.”

Turn Bio designed its nanostructure carriers for individual therapies and different routes of administration. It produces unique formulations to precisely steer the right mRNA or cargo to the right organs, tissues and cell types.

Led by Mouhannad Jumaa, Turn Bio’s CMC team developed eTurna. Jumaa serves as EVP of pharmaceutical development/CMC.

“eTurna caps a lifetime of work to develop new ways to deliver therapies more precisely than ever,” said Jumaa. “It overcomes the final obstacles that have prevented transformational therapies from reaching patients. eTurna will help to redefine patient care.”

Filed Under: Business/Financial News, Drug-Device Combinations, Pharmaceuticals Tagged With: Turn Biotechnologies

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS